Supply of mometasone furoate products by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to address the regulation and quality control of therapeutic goods supplied in Australia. The Act establishes a comprehensive framework for the regulation of therapeutic goods, ensuring they meet safety, quality, and efficacy standards. One specific instance of its application was recorded in a gazette notice on January 24, 2013, where the delegate of the Secretary of the Department of Health and Ageing granted consent for the supply of certain products by Merck Sharp & Dohme Australia Pty Ltd that did not fully comply with labelling requirements. The consent, subject to specific conditions, allowed the continued supply of particular batches of mometasone furoate products with labelling that listed the previous sponsor's details instead of the current supplier's. This decision underscores the Act's role in balancing regulatory compliance with practical considerations in the pharmaceutical supply chain.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the supply, importation, advertising, or sponsorship of therapeutic goods in Australia. This Act covers a broad range of products including medicines, medical devices, blood, and tissues, and encompasses various industries such as pharmaceuticals, biotechnology, and medical device manufacturing. It governs the regulation, approval, and monitoring of therapeutic goods to ensure their safety, quality, and efficacy. The Act applies nationally across Australia, overseen by the Therapeutic Goods Administration (TGA), which is a Commonwealth body. Exclusions and exemptions may apply to certain goods under specific circumstances, such as research and development purposes, and are often detailed in subordinate regulations or orders. The Act’s scope can be extended or modified through the issuance of Therapeutic Goods Orders and Determinations, allowing for flexibility in addressing emerging issues or changes in medical practice. The specific case concerning the supply of mometasone furoate products by Merck Sharp & Dohme Australia Pty Ltd is an example of the Act’s application in allowing for certain deviations from regulatory standards under specific conditions.

Key Provisions

The Therapeutic Goods Act 1989, in this context, authorises the supply of specific batches of therapeutic goods that do not fully comply with certain labelling requirements, as outlined in section 14 and 14A. Specifically, section 14 allows the delegate of the Secretary of the Department of Health and Ageing to provide consent for the supply of goods that are otherwise non-compliant. Section 14A further stipulates that such consent is subject to specific conditions. The consent provided here allows for the supply of batches of mometasone furoate (ELOCON) 1 mg/g in cream tube, ointment tube, and lotion bottle forms, which do not meet the requirement of listing the current sponsor's details on the labels, instead listing the previous sponsor's details. This consent is limited to the identified batches of these products and does not extend to any other changes to the products. The Act imposes several obligations on the parties involved. Firstly, the company, Merck Sharp & Dohme Australia Pty Ltd, must ensure that the products in question are supplied only within the scope of the consent granted. This means adhering strictly to the specified batches and labels. Furthermore, the company must implement arrangements to promptly address any complaints or queries related to these products. Additionally, the company must ensure that the products remain unchanged apart from the labelling issue, adhering to the terms of the consent. The Therapeutic Goods Act 1989 also outlines potential consequences for non-compliance. While the specific section related to penalties is not explicitly mentioned in this notice, breaches of the Act can result in both civil and criminal penalties. For example, section 26 of the Act provides for penalties for contravening the Act or its regulations, which can include fines and imprisonment. Specifically, section 32DA stipulates that a corporation can be fined up to $2,100,000 for serious or repeated contraventions of the Act. Additionally, section 32EA provides for a maximum penalty of $22,000 for individuals found guilty of a contravention. These penalties underscore the importance of complying with the conditions set forth in the consent and the broader regulatory requirements of the Act.